omaveloxolone
Commercial- Indications
- Friedreich's ataxia
Company intelligence / Profile preview
Reata Pharmaceuticals
Plano (formerly Irving), Texas, United Statesbiogen.com ↗
- Ownership
- Public · RETA
- Employees
- ~100
- Development stage
- Commercial
01
Overview
Reata received FDA approval for Skyclarys (omaveloxolone) in March 2023 for treating Friedreich's ataxia in patients 16 years and older, marking its first approved drug in its 21-year history. The company was acquired by Biogen in September 2023 for approximately $7.3 billion.
- Therapeutic areas
- OncologyRare DiseasesImmunologyRheumatologyNeurologyCardiovascularNephrology
- Modalities
- Small moleculessynthetic triterpenoids
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Previously partnered with AbbVie (reacquired rights)Kyowa Kirin Co., Ltd. (for certain Asian markets for bardoxolone)
04
Financials
- Market cap
- $6.6B
- Total revenue
- $22.7M
- Enterprise value
- $6.3B
Beyond the preview
Go deeper on Reata Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reata Pharmaceuticals.